Alpha-Lipoic Acid (ALA)
ApprovedSmall molecule
Alpha-Lipoic Acid (ALA) is one of 120 small molecule programs targeting Peripheral Neuropathy. It is currently in Approved.
4
Indications
4
Total Trials
0
Active Trials
119
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Alpha-Lipoic Acid (ALA)
EEva Pharma
Approved
Brethine
SanofiPreclinical
LCZ696
NovartisPreclinical
Monoferric
PPharmacosmos A/S
Preclinical
Savaysa
Daiichi SankyoPreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Xifaxan
SSalix
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Acei/arb
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetic Polyneuropathy1 trial
Type 1 Diabetes Mellitus1 trial
Peripheral Neuropathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Alpha-Lipoic Acid (ALA). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- EEva Pharma